REGISTER
Prof. Zhu Chen to Donate Full Shaw Prize Award to Chronic Disease Prevention
Prof. Zhu Chen, an academician of the Chinese Academy of Sciences, said at the 2026 Shaw Prize ceremony in Hong Kong that he will donate his share of the award in full to chronic disease prevention and control in China. He shared the 2026 Shaw Prize in Life Science and Medicine with Prof. Anne Dejean and Prof. Hugues de Thé, cited for elucidating the molecular and cellular basis of acute promyelocytic leukemia and for developing a synergistic targeted therapy with a cure rate above 90%.

Prof. Zhu Chen, an academician of the Chinese Academy of Sciences, said at the Shaw Prize award ceremony, held on Tuesday evening at the Hong Kong Convention and Exhibition Centre, that he will donate his share of the prize money in full to chronic disease prevention and control in China. He shared the 2026 Shaw Prize in Life Science and Medicine with the French physicians Prof. Anne Dejean and Prof. Hugues de Thé. The three were cited for elucidating the molecular and cellular basis of acute promyelocytic leukemia (APL) and for pioneering a synergistic targeted therapy, moving the disease from among the deadliest cancers to among the most curable, with cure rates above 90%.

Article Key Points

• Prof. Zhu Chen shares the 2026 Shaw Prize with Prof. Anne Dejean and Prof. Hugues de Thé

• Cited for elucidating the molecular basis of APL and developing a synergistic targeted therapy

• All-trans retinoic acid plus arsenic trioxide, the Shanghai regimen, raised five-year survival above 90%

• Prof. Zhu Chen will donate his full share of the prize money to chronic disease prevention in China

• Prize established in 2002; he is the second Chinese scientist to receive it

From Chemotherapy to Differentiation Therapy

Over the past two decades, Chen has held several senior administrative posts, including Minister of Health, president of the Chinese Red Cross and vice chairman of the Standing Committee of the National People’s Congress. What many readers may not know is that he is also a well-known hematologist.

In the early 1980s, having completed his master’s degree, Chen became a resident physician at Ruijin Hospital of Shanghai Second Medical College. At that time, APL was the most hopeless subtype in the leukemia family, with mortality above 80% and few treatment options.

Chen noted that leukemia does not rank at the front of cancers by incidence, but it ranks tenth by mortality, and that in people under 40 it is the top-ranked tumour, acute leukaemia in particular. APL is the most aggressive form of acute leukaemia in adults.

Internationally, leukaemia was then treated with chemotherapy aimed at killing tumour cells. Under the leadership of Prof. Zhenyi Wang, an academician of the Chinese Academy of Engineering and former director of the Shanghai Institute of Hematology, Chen and his colleagues began to ask a question that had attracted little attention: whether cancer cells that have been killed are broken in every component, or whether only a few genes or a few proteins have gone wrong.

They set out to look for a drug that could induce part of the malignant cells to return to normal. After screening a large number of differentiation-inducing agents, the team found that all-trans retinoic acid (ATRA), a vitamin A derivative used to treat acne and other skin conditions, was highly effective against leukaemic cells. They pioneered the use of ATRA in APL and achieved major clinical success.

Chen said the discovery was, in a sense, a fortunate accident, but that, as Louis Pasteur put it, opportunity belongs to a prepared mind. Had the team not taken a different path, he said, ATRA would not have been found.

The 1986 Patient and the Shanghai Regimen

In 1986, Wang’s wife took on a five-year-old patient with APL as a consultant at Shanghai Children’s Hospital. The child had reached the terminal stage of the disease, and the family had begun to prepare for the worst.

The research team decided that since the drug had proved effective in vitro, it was worth trying in a patient. Within a week the child began to rouse herself, after two weeks her complexion improved, and after a month she was in complete remission. It was the first time in the history of human cancer treatment that a vitamin A derivative had allowed a patient with such an aggressive leukaemia to be given a new life. The girl, who was five at the time, is now 45 and in good health.

In 1988, Wang published the first paper on the clinical application of ATRA in the journal Blood, which drew attention across the international academic community. He handed the task of elucidating the mechanisms of leukaemia and reducing relapse to Chen and to Chen’s wife, Prof. Saijuan Chen. At that time the couple were in France, serving as foreign resident physicians in the haematology laboratory at Saint-Louis Hospital of Université Paris VII while pursuing doctoral and postdoctoral work. Chen also began collaborating with a number of French medical scientists, notably Prof. Anne Dejean and Prof. Hugues de Thé. In 1991 they identified the retinoic acid receptor, which meant they had found the driver gene behind the leukaemia.

Chen said Shanghai research on APL moved from an initial philosophical idea and clinical practice into mechanistic study, and in doing so resolved two key questions: what causes the leukaemia, and why retinoic acid works, with its target pointing directly at the core pathogenic factor.

The work was supported by French colleagues. Her mentor secured 100,000 French francs from the French anticancer fund for the team; the money was not handed over in cash but used to buy the instruments the research urgently needed. Learning that they were about to return to China, the mentor and fellow students also set aside reagents sufficient for one to two years of experiments.

The couple brought back twelve large crates, one of them a metal case packed with dry ice to keep temperature-sensitive reagents cold, and shipped them home.

They then learned that Prof. Tingdong Zhang of Harbin Medical University had been treating patients with APL with arsenic trioxide, the substance commonly called arsenic, using it against the disease. Two teams joined forces to create a revolutionary regimen, the combination of ATRA and arsenic trioxide. This “Shanghai regimen” drew attention from the medical world worldwide, raised five-year survival above 90%, and gradually became the international standard of care for the disease.

Four generations of Chinese physicians have worked in relay since the 1970s to overcome an acute leukaemia once regarded as incurable, spending more than 30 years on the effort. Now in his seventies, Chen still leads a team considering how to extend the research to other types of leukaemia and to other cancers.

The Award and What Comes Next

Chen said he will donate all of his award money to chronic disease prevention and control in China. The prize, named after Run Run Shaw and established in 2002, recognises scientists whose work has had a far-reaching influence on human life. Chen is the second Chinese scientist to receive the honour since the prize was established. According to official Shaw Prize data, 18 Shaw Prize laureates have gone on to win the Nobel Prize as of 2026.

Asked which of his more than twenty titles he valued most, Chen said the identity that matters most to him is academician of the Chinese Academy of Sciences. Asked whether the Nobel Prize was a distant prospect, he said such prizes could not be sought but only encountered.

He hopes the treatment model can be extended to other cancers and reach more patients. In his view, the purpose of research is not to win prizes; prizes are a by-product, and being able to benefit humanity is a scientist’s greatest wish.

0
0
Loading